Nisa Investment Advisors
FATE icon

Nisa Investment Advisors’s Fate Therapeutics FATE Stock Holding History

Nisa Investment Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6K Hold
1,331
– – ﹤0.01% 2658
2025
Q4 		$1.31K Hold
1,331
– – ﹤0.01% 2672
2025
Q3 		$1.68K Buy
1,331
+344
+35% +$371 ﹤0.01% 2653
2025
Q2 		$1.1K Sell
987
-1,323
-57% -$1.54K ﹤0.01% 2717
2025
Q1 		$1.82K Sell
2,310
-14,825
-87% -$18.2K ﹤0.01% 2492
2024
Q4 		$28.3K Sell
17,135
-16
-0.1% -$40 ﹤0.01% 1832
2024
Q3 		$60K Sell
17,151
-351
-2% -$1.37K ﹤0.01% 1596
2024
Q2 		$57.4K Buy
17,502
+365
+2% +$1.6K ﹤0.01% 1625
2024
Q1 		$126K Buy
17,137
+297
+2% +$1.84K ﹤0.01% 1410
2023
Q4 		$63K Buy
16,840
+15,400
+1,069% +$36.4K ﹤0.01% 1573
2023
Q3 		$3.05K Sell
1,440
-109
-7% -$361 ﹤0.01% 2321
2023
Q2 		$7.37K Sell
1,549
-3,956
-72% -$21.8K ﹤0.01% 2298
2023
Q1 		$31K Buy
5,505
+5,205
+1,735% +$31.4K ﹤0.01% 1861
2022
Q4 		$3K Sell
300
-2,162
-88% -$40.6K ﹤0.01% 2336
2022
Q3 		$51K Buy
2,462
+362
+17% +$10.5K ﹤0.01% 1731
2022
Q2 		$52K Sell
2,100
-260
-11% -$7.17K ﹤0.01% 1717
2022
Q1 		$91K Sell
2,360
-180
-7% -$6.97K ﹤0.01% 1647
2021
Q4 		$105K Sell
2,540
-360
-12% -$20.4K ﹤0.01% 1499
2021
Q3 		$172 Sell
2,900
-200
-6% -$15.7K ﹤0.01% 1463
2021
Q2 		$269 Sell
3,100
-430
-12% -$34.6K ﹤0.01% 1315
2021
Q1 		$291 Sell
3,530
-400
-10% -$38.3K ﹤0.01% 1354
2020
Q4 		$357K Buy
3,930
+1,475
+60% +$91.6K ﹤0.01% 1267
2020
Q3 		$98K Buy
2,455
+1,900
+342% +$66.3K ﹤0.01% 1549
2020
Q2 		$19K Buy
555
+30
+6% +$894 ﹤0.01% 1784
2020
Q1 		$12K Sell
525
-75
-13% -$1.9K ﹤0.01% 1816
2019
Q4 		$12K Hold
600
– – ﹤0.01% 1798
2019
Q3 		$9K Buy
600
+170
+40% +$3.26K ﹤0.01% 1805
2019
Q2 		$9K Hold
430
– – ﹤0.01% 1776
2019
Q1 		$8K Hold
430
– – ﹤0.01% 1814
2018
Q4 		$6K Hold
430
– – ﹤0.01% 1766
2018
Q3 		$7K Buy
+430
New +$5.08K ﹤0.01% 1805

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's FATE Position: Q1 2026 in Review

Nisa Investment Advisors held its Fate Therapeutics (FATE) position steady in Q1 2026 at 1,331 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

Nisa Investment Advisors first reported a position in FATE in Q3 2018 and has held it in 31 quarters since. The position peaked at $357K in Q4 2020. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Nisa Investment Advisors held 1,331 shares of Fate Therapeutics worth $1.6K as of Q1 2026.
  • Nisa Investment Advisors left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2658 holding.
  • Nisa Investment Advisors first reported a position in Fate Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Nisa Investment Advisors's Fate Therapeutics position peaked at $357K in Q4 2020.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.